We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
- Authors
Kopylov, Uri; Seidman, Ernest
- Abstract
Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple clinical, genetic and immunopharmacological factors may impact the response to anti-TNFs. Early stratification of IBD patients by the expected risk of therapeutic failure during the induction and maintenance phases of treatment may allow for treatment optimization and potentially optimal short- and long-term outcomes. The aim of this review is to summarize the current data concerning the potential predictors of therapeutic success and failure of anti-TNFs in IBD.
- Publication
Therapeutic Advances in Gastroenterology, 2016, Vol 9, Issue 4, p513
- ISSN
1756-283X
- Publication type
Article
- DOI
10.1177/1756283X16638833